{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:44:22Z","timestamp":1648719862026},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T00:00:00Z","timestamp":1467072000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00103-016-2382-z","type":"journal-article","created":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T06:13:13Z","timestamp":1467094393000},"page":"970-978","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trends in der Arzneimittelversorgung von M\u00e4nnern"],"prefix":"10.1007","volume":"59","author":[{"given":"Gerd","family":"Glaeske","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,28]]},"reference":[{"key":"2382_CR1","volume-title":"Bewertender Arzneimittel-Index. Hypnotika, Sedativa und Psychopharmaka. Verordnungsverhaltend und Verordnungsh\u00e4ufigkeit. XXIV-XXIX","author":"E Greiser","year":"1983","unstructured":"Greiser E (1983) Bewertender Arzneimittel-Index. Hypnotika, Sedativa und Psychopharmaka. Verordnungsverhaltend und Verordnungsh\u00e4ufigkeit. XXIV-XXIX. Medpharm, Wiesbaden"},{"key":"2382_CR2","volume-title":"Interessenkonflikte in der Medizin","year":"2011","unstructured":"Lieb K, Klemperer D, Ludwig W\u2011D (Hrsg) (2011) Interessenkonflikte in der Medizin. Springer, Heidelberg"},{"key":"2382_CR3","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00120-015-4008-8","volume":"54","author":"G Glaeske","year":"2015","unstructured":"Glaeske G (2015) 70 plus als Einschlusskriterium \u2013 nicht als Ausschluss. Urologe 54:1739\u20131746","journal-title":"Urologe"},{"key":"2382_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.322.7290.832","volume":"322","author":"J Hippisley-Cox","year":"2001","unstructured":"Hippisley-Cox J, Pringle M, Crwon N et al (2001) Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 322:1\u20135","journal-title":"BMJ"},{"key":"2382_CR5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00392-004-0157-2","volume":"93","author":"H Theres","year":"2004","unstructured":"Theres H, Maier B, Matteucci Gothe R et al (2004) Influence of gender on treatment and short-term mortality of patients with acute myocardial infarction in Berlin. Z Kardiol 93:954\u2013963","journal-title":"Z Kardiol"},{"key":"2382_CR6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1055\/s-2006-942089","volume":"82","author":"PA Th\u00fcrmann","year":"2006","unstructured":"Th\u00fcrmann PA (2006) Geschlechtsspezifische Aspekte in der Pharmakotherapie \u2013 was ist gesichert? Z Allg Med 82:380\u2013384","journal-title":"Z Allg Med"},{"key":"2382_CR7","volume-title":"BARMER GEK Arzneimittelreport","author":"G Glaeske","year":"2012","unstructured":"Glaeske G, Schicktanz C (2012) BARMER GEK Arzneimittelreport. Asgard, St. Augustin"},{"key":"2382_CR8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s00103-005-1039-0","volume":"5","author":"PA Th\u00fcrmann","year":"2005","unstructured":"Th\u00fcrmann PA (2005) Geschlechtsspezifische Unterschiede in der Pharmakokinetik und -dynamik von Arzneimitteln. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 5:536\u2013540","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"2382_CR9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2006.08.004","volume":"80","author":"PA Th\u00fcrmann","year":"2006","unstructured":"Th\u00fcrmann PA, Haack S, Werner U et al (2006) Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex dependent. Clin Pharmacol Ther 80:551\u2013553","journal-title":"Clin Pharmacol Ther"},{"key":"2382_CR10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/clpt.1985.216","volume":"38","author":"T Walle","year":"1985","unstructured":"Walle T, Byington RP, Furberg CD et al (1985) Biological determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther 38:509\u2013518","journal-title":"Clin Pharmacol Ther"},{"key":"2382_CR11","first-page":"149","volume-title":"Sex and gender differences in pharmacology","author":"G Glaeske","year":"2012","unstructured":"Glaeske G, Gerdau-Heitmann C, H\u00f6fel F et al (2012) Gender specific drug prescription in germany, results from prescriptions analyses. In: Regitz-Zagrosek V (Hrsg) Sex and gender differences in pharmacology. Springer, Heidelberg, S 149\u2013168"},{"key":"2382_CR12","volume-title":"BARMER GEK Arzneimittelreport","author":"G Glaeske","year":"2015","unstructured":"Glaeske G, Schicktanz C (2015) BARMER GEK Arzneimittelreport. Asgard, St. Augustin"},{"key":"2382_CR13","first-page":"613","volume-title":"Arzneiverordnungsreport","year":"1997","unstructured":"Schwabe U, Paffrath D (Hrsg) (1997) Arzneiverordnungsreport. Springer, Heidelberg, S\u00a0613"},{"issue":"3","key":"2382_CR14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"WHI","year":"2002","unstructured":"WHI (2002) Writing group for the women\u2019s health initiative investigators: risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the women\u2019s health initiative randomized controlled trial. JAMA 288(3):321\u2013333","journal-title":"JAMA"},{"key":"2382_CR15","unstructured":"Glaeske G (2015) Psychopharmaka im Fokus. Herausforderung f\u00fcr die Versorgung. Was hat sich seit der Einf\u00fchrung der Antidepressiva ver\u00e4ndert. 21. Hauptstadtsymposium der DGPPN. http:\/\/www.dgppn.de\/fileadmin\/user_upload\/_medien\/download\/pdf\/pressemitteilungen\/2015\/2015-09-08_Glaeske.pdf . Zugegriffen: 5. M\u00e4rz 2016"},{"key":"2382_CR16","volume-title":"Hirndoping. Warum wir nicht alles schlucken sollten","author":"K Lieb","year":"2010","unstructured":"Lieb K (2010) Hirndoping. Warum wir nicht alles schlucken sollten. Artemis & Winkler, Mannheim"},{"key":"2382_CR17","volume-title":"Der Pharmazeutische Markt in Deutschland (DPM)","author":"IMS \u2013 Institut f\u00fcr Medizinische Statistik","year":"2015","unstructured":"IMS \u2013 Institut f\u00fcr Medizinische Statistik (2015) Der Pharmazeutische Markt in Deutschland (DPM). IMS Health, Frankfurt a. M."},{"key":"2382_CR18","first-page":"53","volume":"6","author":"arznei-telegramm","year":"1998","unstructured":"arznei-telegramm (1998) Arzneimittelsicherheit und Viagra \u2013 Pl\u00e4doyer f\u00fcr die einstweilige Marktr\u00fccknahme. Arzneitelegramm 6:53\u201354","journal-title":"Arzneitelegramm"},{"key":"2382_CR19","unstructured":"ABDA (2015) Faktenblatt Arzneimittelf\u00e4lschungen, Stand 22.6.2015, Berlin"},{"issue":"2","key":"2382_CR20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3224\/fzg.v21i2.20935","volume":"21","author":"N Wehner","year":"2015","unstructured":"Wehner N, Baumgarten D, Luck F, Maihofer A, Zemp E (2015) \u201eMir geht es gut!\u201c Gesundheitsvorstellungen von M\u00e4nnern in der Schweiz. Ergebnisse aus einem empirischen Projekt. Freibg Z Geschlechterstud 21(2):33\u201349","journal-title":"Freibg Z Geschlechterstud"},{"key":"2382_CR21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1067\/mjd.2002.124088","volume":"47","author":"EA Olsen","year":"2002","unstructured":"Olsen EA, Dunlap FE, Funicella T et\u00a0al (2002) A randomized clinical trial of 5\u202f% topical minoxidil versus 2\u202f% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J\u00a0Am Acad Dermatol 47:377\u2013385","journal-title":"J Am Acad Dermatol"},{"key":"2382_CR22","first-page":"11","volume":"10","author":"UP Mache","year":"1988","unstructured":"Mache UP (1988) Minoxidil-L\u00f6sung. Synopsis. Pharma Krit 10:11\u201312","journal-title":"Pharma Krit"},{"key":"2382_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199607043350101","volume":"335","author":"S Bhasin","year":"1996","unstructured":"Bhasin S, Storer TW, Berman N et\u00a0al (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335:1\u20137","journal-title":"N Engl J Med"},{"key":"2382_CR24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1506119","volume":"374","author":"PJ Snyder","year":"2016","unstructured":"Snyder PJ, Bhasin S, Cunningham GR, et\u00a0al. for the Testosterone Trials Investigators (2016) Effects of testosterone treatment in older men. N Engl J Med 374:611\u2013624","journal-title":"N Engl J Med"},{"key":"2382_CR25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","volume":"363","author":"S Basaria","year":"2010","unstructured":"Basaria S, Coviello AD, Travison TG et\u00a0al (2010) Adverse events associated with testosterone administration. N Eng J Med 363:109\u2013122","journal-title":"N Eng J Med"},{"key":"2382_CR26","first-page":"2117","volume":"137","author":"A Hilbert-Walter","year":"2013","unstructured":"Hilbert-Walter A, B\u00fcttner R, Sieber C et al (2013) Testosteron im Alter: ein Update. Dtsch Med Wochenschr 137:2117\u20132122","journal-title":"Dtsch Med Wochenschr"},{"key":"2382_CR27","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/CIRCHEARTFAILURE.109.931063","volume":"3","author":"AL Baggish","year":"2010","unstructured":"Baggish AL, Weiner RB, Kanayama G et al (2010) Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail 3:472\u2013476","journal-title":"Circ Heart Fail"},{"key":"2382_CR28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","volume":"73","author":"K Mann","year":"2013","unstructured":"Mann K, Bladstr\u00f6m A, Torup L et al (2013) Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatr 73:706\u2013713","journal-title":"Biol Psychiatr"},{"key":"2382_CR29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","volume":"48","author":"W Brink van den","year":"2013","unstructured":"van den Brink W, Aubin HJ, Bladstr\u00f6m A et al (2013) Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6\u2011month studies. Alcohol 48:570\u2013578","journal-title":"Alcohol"},{"key":"2382_CR30","doi-asserted-by":"publisher","first-page":"e005376","DOI":"10.1136\/bmjopen-2014-005376","volume":"4","author":"P Laram\u00e9e","year":"2014","unstructured":"Laram\u00e9e P, Brodtkorb T\u2011H, Rahhali N et al (2014) The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high\/very high drinking risk levels: a Markov model. BMJ Open 4:e005376. doi:10.1136\/bmjopen-2014-005376","journal-title":"BMJ Open"},{"issue":"12","key":"2382_CR31","doi-asserted-by":"publisher","first-page":"e1001924","DOI":"10.1371\/journal.pmed.1001924","volume":"12","author":"C Palpacuer","year":"2015","unstructured":"Palpacuer C, Laviolle B, Boussageon R, Reymann JM, Bellissant E, Naudet F (2015) Risks and benefits of Nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med 12(12):e1001924. doi:10.1371\/journal.pmed.1001924","journal-title":"PLoS Med"},{"key":"2382_CR32","first-page":"150","volume":"23","author":"Keine Autoren gelistet","year":"2014","unstructured":"Keine Autoren gelistet (2014) Nalmefen \u2013 Alcohol dependence: no advance. Prescrire Int 23:150\u2013152","journal-title":"Prescrire Int"},{"key":"2382_CR33","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1210\/jc.2007-2768","volume":"93","author":"PY Liu","year":"2013","unstructured":"Liu PY, Swerdloff RS, Anawalt BD et\u00a0al (2013) Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J\u00a0Clin Endocrinol Metab 93:1774\u20131783","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-016-2382-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00103-016-2382-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-016-2382-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T17:19:43Z","timestamp":1498324783000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00103-016-2382-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,28]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1007\/s00103-016-2382-z","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,28]]}}}